We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+9.14%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$727M
AUM Growth
-$47.6M
Cap. Flow
-$46.8M
Cap. Flow %
-6.44%
Top 10 Hldgs %
82.71%
Holding
37
New
2
Increased
11
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$40.1M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14.8M
3
COGT icon
Cogent Biosciences
COGT
+$14M
4
TSVT
2seventy bio
TSVT
+$12.2M
5
VRDN icon
Viridian Therapeutics
VRDN
+$4.26M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$119M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.6M
4
GSK icon
GSK
GSK
+$17.7M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 89.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$141M 19.41%
2,900,000
-18,237
-0.6% -$930K
CLDX icon
2
Celldex Therapeutics
CLDX
$2.77B
$88.2M 12.13%
2,600,000
+1,190,549
+84% +$40.1M
ARGX icon
3
PUT
argenx
ARGX
$57.4B
$71.8M 9.88%
184,300
+179,800
+3,996% +$70.7M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$68.3M 9.39%
3,262,004
+56,018
+2% +$1.17M
PCVX icon
5
Vaxcyte
PCVX
$7.89B
$64.9M 8.93%
1,300,000
+83,216
+7% +$3.94M
TSVT
6
DELISTED
2seventy bio
TSVT
$49.5M 6.81%
4,890,706
+1,151,734
+31% +$12.2M
VERA icon
7
Vera Therapeutics
VERA
$2.54B
$48.1M 6.62%
3,000,000
-372,428
-11% -$3.36M
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.75B
$26.9M 3.71%
975,298
-399,702
-29% -$10M
TVTX icon
9
Travere Therapeutics
TVTX
$5.33B
$22.3M 3.07%
1,454,730
-108,865
-7% -$1.98M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.37B
$20.1M 2.76%
2,848,197
+1,848,197
+185% +$14.8M
COGT icon
11
Cogent Biosciences
COGT
$6.79B
$19.1M 2.63%
1,617,391
+1,217,417
+304% +$14M
BNR
12
Burning Rock Biotech
BNR
$94.4M
$18.3M 2.52%
850,000
+47,937
+6% +$1.27M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.13B
$16.9M 2.32%
709,498
+165,895
+31% +$4.26M
WVE icon
14
Wave Life Sciences
WVE
$1.12B
$14.3M 1.96%
3,924,602
+116,726
+3% +$471K
AMRN
15
Amarin Corp
AMRN
$284M
$14.3M 1.96%
600,000
– –
LQDA icon
16
Liquidia Corp
LQDA
$7.67B
$12.9M 1.77%
1,642,244
– –
OLMA icon
17
Olema Pharmaceuticals
OLMA
$1.02B
$11.8M 1.62%
1,304,332
-707,521
-35% -$4.27M
STRO icon
18
Sutro Biopharma
STRO
$379M
$6.97M 0.96%
150,000
+59,816
+66% +$2.98M
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$4.51M 0.62%
729,077
– –
PBYI icon
20
Puma Biotechnology
PBYI
$406M
$1.67M 0.23%
473,070
– –
KYNB
21
CALL
Kyntra Bio
KYNB
$28.5M
$1.58M 0.22%
+23,460
New +$9.7M
RYTM icon
22
Rhythm Pharmaceuticals
RYTM
$7B
$1.53M 0.21%
92,602
– –
PTCT icon
23
CALL
PTC Therapeutics
PTCT
$6.37B
$1.16M 0.16%
+28,500
New +$1.39M
CNTB
24
Connect Biopharma Holdings
CNTB
$135M
$603K 0.08%
535,005
-204,644
-28% -$229K
NGNE icon
25
Neurogene
NGNE
$696M
$99.6K 0.01%
5,998
– –
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Kynam Capital Management held 37 positions worth $727M, down 6.1% from $775M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Kynam Capital Management withdrew a net $46.8M in Q2 2023, closing 11 positions and reducing 6 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $119M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 100% a quarter earlier.

Against the trend, Kynam Capital Management added an estimated $40.1M to Celldex Therapeutics.

  • Kynam Capital Management added most to Celldex Therapeutics in Q2 2023, an estimated $40.1M increase.
  • Kynam Capital Management's biggest Q2 2023 reduction was Protagonist Therapeutics, cutting an estimated $10M.
  • Kynam Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $119M.
  • Kynam Capital Management's ten largest holdings make up 83% of its $727M portfolio in Q2 2023.
  • Kynam Capital Management opened 2 new positions and closed 11 in Q2 2023.
  • Kynam Capital Management's portfolio value fell 6.1% quarter-over-quarter to $727M.

Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.